Hypermethylator phenotype in sporadic colon cancer: Study on a population-based series of 582 cases

Ludovic Barault, Céline Charon-Barra, Valérie Jooste, Mathilde Funes De La Vega, Laurent Martin, Patrick Roignot, Patrick Rat, Anne Marie Bouvier, Pierre Laurent-Puig, Jean Faivre, Caroline Chapusot, Francoise Piard

Research output: Contribution to journalArticle

Abstract

The CpG island methylator phenotype (CIMP) is a distinct phenotype in colorectal cancer, associated with specific clinical, pathologic, and molecular features. However, most of the studies stratified methylation according to two subgroups (CIMP-High versus No-CIMP/CIMP-Low). In our study, we defined three different subgroups of methylation (No-CIMP, CIMP-Low, and CIMP-High) and evaluated the prognostic significance of methylation status on a population-based series of sporadic colon cancers. A total of 582 colon adenocarcinomas were evaluated using methylation-specific PCR for 5 markers (hMLH1, P16, MINT1, MINT2, and MINT31). No-CIMP status was defined as no methylated locus, CIMP-Low status as one to three methylated loci, and CIMP-High status as four or five methylated loci. Clinicopathologic and molecular characteristics were correlated to the methylation status. Crude and relative survival was compared according to methylation status. In the microsatellite-stable (MSS) group, CIMP-High was significantly associated with proximal location (P = 0.011) and BRAF mutation (P <0.001). KRAS mutations were more associated with CIMP-High and CIMP-Low status (P = 0.008). A shorter 5-year survival was observed in MSS cancer patients with CIMP-Low or CIMP-High status. These results remained significant in multivariate analysis adjusted for age, stage, and BRAF and KRAS mutational status [CIMP-Low: hazard ratio (HR), 1.85; 95% confidence interval (95% CI), 1.37-2.51; CIMP-High, HR, 2.90; 95% CI, 1.53-5.49 compared with No-CIMP]. Within the high-level microsatellite instability group, no difference in survival was observed between the different CIMP groups. Our results show the interest of defining three subgroups of patients according to their methylation status (No-CIMP/CIMP-Low/CIMP-High). Methylation is an independent prognostic factor in MSS colon cancer.

Original languageEnglish
Pages (from-to)8541-8546
Number of pages6
JournalCancer Research
Volume68
Issue number20
DOIs
Publication statusPublished - Oct 15 2008

Fingerprint

CpG Islands
Colonic Neoplasms
Phenotype
Population
Methylation
Microsatellite Repeats
Survival
Confidence Intervals

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Barault, L., Charon-Barra, C., Jooste, V., De La Vega, M. F., Martin, L., Roignot, P., ... Piard, F. (2008). Hypermethylator phenotype in sporadic colon cancer: Study on a population-based series of 582 cases. Cancer Research, 68(20), 8541-8546. https://doi.org/10.1158/0008-5472.CAN-08-1171

Hypermethylator phenotype in sporadic colon cancer : Study on a population-based series of 582 cases. / Barault, Ludovic; Charon-Barra, Céline; Jooste, Valérie; De La Vega, Mathilde Funes; Martin, Laurent; Roignot, Patrick; Rat, Patrick; Bouvier, Anne Marie; Laurent-Puig, Pierre; Faivre, Jean; Chapusot, Caroline; Piard, Francoise.

In: Cancer Research, Vol. 68, No. 20, 15.10.2008, p. 8541-8546.

Research output: Contribution to journalArticle

Barault, L, Charon-Barra, C, Jooste, V, De La Vega, MF, Martin, L, Roignot, P, Rat, P, Bouvier, AM, Laurent-Puig, P, Faivre, J, Chapusot, C & Piard, F 2008, 'Hypermethylator phenotype in sporadic colon cancer: Study on a population-based series of 582 cases', Cancer Research, vol. 68, no. 20, pp. 8541-8546. https://doi.org/10.1158/0008-5472.CAN-08-1171
Barault, Ludovic ; Charon-Barra, Céline ; Jooste, Valérie ; De La Vega, Mathilde Funes ; Martin, Laurent ; Roignot, Patrick ; Rat, Patrick ; Bouvier, Anne Marie ; Laurent-Puig, Pierre ; Faivre, Jean ; Chapusot, Caroline ; Piard, Francoise. / Hypermethylator phenotype in sporadic colon cancer : Study on a population-based series of 582 cases. In: Cancer Research. 2008 ; Vol. 68, No. 20. pp. 8541-8546.
@article{d7cb1026ad534645aaff815d32f630d6,
title = "Hypermethylator phenotype in sporadic colon cancer: Study on a population-based series of 582 cases",
abstract = "The CpG island methylator phenotype (CIMP) is a distinct phenotype in colorectal cancer, associated with specific clinical, pathologic, and molecular features. However, most of the studies stratified methylation according to two subgroups (CIMP-High versus No-CIMP/CIMP-Low). In our study, we defined three different subgroups of methylation (No-CIMP, CIMP-Low, and CIMP-High) and evaluated the prognostic significance of methylation status on a population-based series of sporadic colon cancers. A total of 582 colon adenocarcinomas were evaluated using methylation-specific PCR for 5 markers (hMLH1, P16, MINT1, MINT2, and MINT31). No-CIMP status was defined as no methylated locus, CIMP-Low status as one to three methylated loci, and CIMP-High status as four or five methylated loci. Clinicopathologic and molecular characteristics were correlated to the methylation status. Crude and relative survival was compared according to methylation status. In the microsatellite-stable (MSS) group, CIMP-High was significantly associated with proximal location (P = 0.011) and BRAF mutation (P <0.001). KRAS mutations were more associated with CIMP-High and CIMP-Low status (P = 0.008). A shorter 5-year survival was observed in MSS cancer patients with CIMP-Low or CIMP-High status. These results remained significant in multivariate analysis adjusted for age, stage, and BRAF and KRAS mutational status [CIMP-Low: hazard ratio (HR), 1.85; 95{\%} confidence interval (95{\%} CI), 1.37-2.51; CIMP-High, HR, 2.90; 95{\%} CI, 1.53-5.49 compared with No-CIMP]. Within the high-level microsatellite instability group, no difference in survival was observed between the different CIMP groups. Our results show the interest of defining three subgroups of patients according to their methylation status (No-CIMP/CIMP-Low/CIMP-High). Methylation is an independent prognostic factor in MSS colon cancer.",
author = "Ludovic Barault and C{\'e}line Charon-Barra and Val{\'e}rie Jooste and {De La Vega}, {Mathilde Funes} and Laurent Martin and Patrick Roignot and Patrick Rat and Bouvier, {Anne Marie} and Pierre Laurent-Puig and Jean Faivre and Caroline Chapusot and Francoise Piard",
year = "2008",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-08-1171",
language = "English",
volume = "68",
pages = "8541--8546",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Hypermethylator phenotype in sporadic colon cancer

T2 - Study on a population-based series of 582 cases

AU - Barault, Ludovic

AU - Charon-Barra, Céline

AU - Jooste, Valérie

AU - De La Vega, Mathilde Funes

AU - Martin, Laurent

AU - Roignot, Patrick

AU - Rat, Patrick

AU - Bouvier, Anne Marie

AU - Laurent-Puig, Pierre

AU - Faivre, Jean

AU - Chapusot, Caroline

AU - Piard, Francoise

PY - 2008/10/15

Y1 - 2008/10/15

N2 - The CpG island methylator phenotype (CIMP) is a distinct phenotype in colorectal cancer, associated with specific clinical, pathologic, and molecular features. However, most of the studies stratified methylation according to two subgroups (CIMP-High versus No-CIMP/CIMP-Low). In our study, we defined three different subgroups of methylation (No-CIMP, CIMP-Low, and CIMP-High) and evaluated the prognostic significance of methylation status on a population-based series of sporadic colon cancers. A total of 582 colon adenocarcinomas were evaluated using methylation-specific PCR for 5 markers (hMLH1, P16, MINT1, MINT2, and MINT31). No-CIMP status was defined as no methylated locus, CIMP-Low status as one to three methylated loci, and CIMP-High status as four or five methylated loci. Clinicopathologic and molecular characteristics were correlated to the methylation status. Crude and relative survival was compared according to methylation status. In the microsatellite-stable (MSS) group, CIMP-High was significantly associated with proximal location (P = 0.011) and BRAF mutation (P <0.001). KRAS mutations were more associated with CIMP-High and CIMP-Low status (P = 0.008). A shorter 5-year survival was observed in MSS cancer patients with CIMP-Low or CIMP-High status. These results remained significant in multivariate analysis adjusted for age, stage, and BRAF and KRAS mutational status [CIMP-Low: hazard ratio (HR), 1.85; 95% confidence interval (95% CI), 1.37-2.51; CIMP-High, HR, 2.90; 95% CI, 1.53-5.49 compared with No-CIMP]. Within the high-level microsatellite instability group, no difference in survival was observed between the different CIMP groups. Our results show the interest of defining three subgroups of patients according to their methylation status (No-CIMP/CIMP-Low/CIMP-High). Methylation is an independent prognostic factor in MSS colon cancer.

AB - The CpG island methylator phenotype (CIMP) is a distinct phenotype in colorectal cancer, associated with specific clinical, pathologic, and molecular features. However, most of the studies stratified methylation according to two subgroups (CIMP-High versus No-CIMP/CIMP-Low). In our study, we defined three different subgroups of methylation (No-CIMP, CIMP-Low, and CIMP-High) and evaluated the prognostic significance of methylation status on a population-based series of sporadic colon cancers. A total of 582 colon adenocarcinomas were evaluated using methylation-specific PCR for 5 markers (hMLH1, P16, MINT1, MINT2, and MINT31). No-CIMP status was defined as no methylated locus, CIMP-Low status as one to three methylated loci, and CIMP-High status as four or five methylated loci. Clinicopathologic and molecular characteristics were correlated to the methylation status. Crude and relative survival was compared according to methylation status. In the microsatellite-stable (MSS) group, CIMP-High was significantly associated with proximal location (P = 0.011) and BRAF mutation (P <0.001). KRAS mutations were more associated with CIMP-High and CIMP-Low status (P = 0.008). A shorter 5-year survival was observed in MSS cancer patients with CIMP-Low or CIMP-High status. These results remained significant in multivariate analysis adjusted for age, stage, and BRAF and KRAS mutational status [CIMP-Low: hazard ratio (HR), 1.85; 95% confidence interval (95% CI), 1.37-2.51; CIMP-High, HR, 2.90; 95% CI, 1.53-5.49 compared with No-CIMP]. Within the high-level microsatellite instability group, no difference in survival was observed between the different CIMP groups. Our results show the interest of defining three subgroups of patients according to their methylation status (No-CIMP/CIMP-Low/CIMP-High). Methylation is an independent prognostic factor in MSS colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=54249165951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54249165951&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-1171

DO - 10.1158/0008-5472.CAN-08-1171

M3 - Article

C2 - 18922929

AN - SCOPUS:54249165951

VL - 68

SP - 8541

EP - 8546

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 20

ER -